• Quotes
  • Shortcuts
The Executive's Internet
Tues, Oct 27th
editor corner icon Editor's Corner | Archive
Steps to Help You Get Out of Your Own Way: These research-based tips will help you slow down, fight the fog, and improve both your home life and work life. Patricia
icon
GoogleAmazonWikipedia
site of the day icon Site of the Day | Archive
Information is Beautiful
Distilling the world's data, information & knowledge into beautiful infographics & visualizations


spacerspacer

 

 BUSINESS/FINANCE NEWS
Setup News Ticker
   BUSINESS/FINANCE NEWS
Searching for 'Covid-19'. (Return)

CNBC FinanceOct 27, 2020
Stock futures rise as market tries to rebound from Monday's big sell-off
On Monday, equities plunged in their worst session since September amid a surge in Covid-19 cases across the country.

MarketWatchOct 27, 2020
Metals Stocks: Gold's price rally takes a breather as stocks stage modest bounce from Monday skid
Gold futures early Tuesday hold steady as indications for a tepid rebound in equities, following Monday's stock-market rout due to rising COVID-19 cases, cause some pause in bullion buying.

RELATED ARTICLES
European stocks extend losses on Covid-19 surge (FT.com - Financial Markets)

MarketWatch MarketPulseOct 27, 2020
Pfizer cites $500 million impact in the third quarter as a result of the COVID-19 pandemic
Shares of Pfizer Inc. were up 0.1% in premarket trading on Tuesday after the drug maker missed sales expectations for the quarter. Pfizer had earnings of $2.2 billion, or 39 cents per share, in the third quarter of 2020, down from $7.7 billion, or $1.36 per share, in the same quarter a year ago. It had adjusted earnings per share of 72 cents for the quarter, against a FactSet consensus of 71 cents. The drug company's revenue fell 4% to $12.1 billion for the quarter, compared with $12.7 billion in the same quarter a year ago. The FactSet consensus was $12.3 billion. The company attributed an estimated unfavorable impact of $500 million for the quarter to the COVID-19 pandemic, citing lower demand for anti-infective products used in surgeries in China and disruptions in traditional prescribing patterns in the U.S. as people avoided going to to the doctor, including a 19% drop in sales of its smoking-cessation drug Chantix. The impact was offset to some degree by "strong performance" of its heart drugs, Vyndaqel and Vyndamax, and its biosimilars business. It did not disclose any additional details about its work to develop a COVID-19 vaccine with BioNTech . However, it did note that the Phase 2/3 clinical trial for the vaccine candidate had enrolled 42,000 participants as of Monday, and about 85% of the participants have received their second and final dose of the experimental vaccine. Pfizer adjusted its 2020 guidance for adjusted earning share to $2.88 to $2.93, from $2.85 to $2.95. Pfizer's stock is down 3.2% for the year, compared with the S&P 500 , which has gained 5.2%.

Market Pulse Stories are Rapid-fire, short news bursts on stocks and markets as they move. Visit MarketWatch.com for more information on this news.



MarketWatch MarketPulseOct 27, 2020
Coronavirus tally: Global cases of COVID-19 top 43.5 million, 1.16 million deaths and U.S. 7-day case tally sets record
The global tally for confirmed cases of the coronavirus that causes COVID-19 climbed above 43.5 million on Tuesday, according to data aggregated by Johns Hopkins University, while the death toll rose to 1.16 million. The U.S. has the highest case total at 8.7 million and deaths at 225,735. The U.S. has averaged 71,000 new cases a day in the last week, it's highest for a 7-day period since the start of the outbreak, the New York Times reported. Brazil has the second highest death toll at 157,397 and is third by cases at 5.4 million. India is second in cases with 7.9 million, and third in deaths at 119,502. Mexico has the fourth highest death toll at 89,171 and ninth highest case tally at 895,326. The U.K has 45,088 deaths, the highest in Europe and fifth highest in the world, and 897,740 cases.

Market Pulse Stories are Rapid-fire, short news bursts on stocks and markets as they move. Visit MarketWatch.com for more information on this news.



Wall Street Journal US BusinessOct 27, 2020
3M Sales Rise From Personal-Safety, Home-Improvement Products
The manufacturer's profit fell as expenses grew and demand for products serving industries affected by the Covid-19 pandemic continued to decline.

Yahoo BusinessOct 27, 2020
Oppenheimer: These 3 Stocks Are Poised to Surge by at Least 60%
It's down to the wire. The U.S. Presidential elections are only a week away, and with the polls showing Biden has an edge over President Trump, investors are preparing.Oppenheimer's Chief Investment Strategist John Stoltzfus points out that last week, stocks churned as investors rebalanced their portfolios, rotating and adding additional exposure to value stocks "while others took profits in growth names that had previously run-up substantially ahead of what could be higher capital gains and other taxes next year," in the event that the Democrats come out on top.Highlighting that the expectation of an effective COVID-19 vaccine is behind the broadening of investor appetite for equities, Stoltzfus argues this renewed appetite " improves the attractiveness of value stocks."Going forward, the strategist notes the Federal Reserve's efforts "underscore the case for the economy's recovery and the equity markets' resilience and potential from here." Although a "blue wave" is seen as a potential risk, Stoltzfus thinks this outcome is very unlikely, and that continued split control should alleviate market worries.Taking Stoltzfus' outlook into consideration, our attention turned to three stocks Oppenheimer analysts believe can surge by at least 70% in the year ahead. Running the tickers through TipRanks' database, we found out that each boasts a "Strong Buy" consensus rating from the broader analyst community.Chromadex (CDXC)Focused on improving the way people age, Chromadex operates as a science-based integrated

MarketWatchOct 27, 2020
Coronavirus update: U.S. case tally tops 8.7 million and marks seven-day record, with more than 20 states seeing most new cases since start of the outbreak
The U.S. case tally for the coronavirus illness COVID-19 climbed above 8.7 million on Tuesday, with more than 20 states counting record numbers of new infections, as more business curfews were announced to combat the spread.

MarketWatch Breaking NewsOct 27, 2020
European stocks struggle as investors juggle earnings with COVID-19 resurgence
European stocks struggle as investors juggle earnings with COVID-19 resurgence

RELATED ARTICLES
Europe Markets: European stocks sluggish as investors balance earnings beats with COVID-19 wave (MarketWatch)

MarketWatch Breaking NewsOct 27, 2020
COVID-19 immunity may only last a few months after infection, study indicates
COVID-19 immunity may only last a few months after infection, study indicates

RELATED ARTICLES
: COVID-19 immunity may only last a few months after infection, study indicates (MarketWatch)

Yahoo BusinessOct 27, 2020
Yes, Tesla Beat Earnings — and Yes, Tesla Stock Is Still a Sell, Says Analyst
For a day that marked Tesla's (TSLA) fifth straight quarter of reporting positive profits, last week's 0.7% increase in the share price of Tesla stock seemed somewhat underwhelming.Reporting earnings Wednesday night, Tesla closed trading Thursday up only modestly, and really, only barely outperforming the S&P 500's overall 0.5% move. Tesla called Q3 its "best quarter in history," with pro forma earnings coming in 36% ahead of expectations at $0.76 per share, sales of $8.8 billion about 6% better than predicted, and free cash flowing strongly -- $1.9 billion over the past 12 months.Tesla told investors Wednesday that it remains on target to produce and deliver half a million electric cars this year, despite the fact that "this goal has become more difficult" to achieve in the face of Covid-19. Cybertruck deliveries are expected to begin late next year. Even Tesla's "energy" business -- solar roofs and solar storage -- looks "poised for strong growth," said the company.Much of Wall Street applauded the news, with R.W. Baird and JMP Securities both upgrading Tesla shares to "outperform" and Piper Sandler calling Tesla a "must-own" stock, and as both Oppenheimer and RBC Capital raised price targets on the shares. One analyst, however, stood out from the crowd for his continued pessimism on Tesla:Gordon Johnson of GLJ Research says Tesla is still a "sell."Urging investors not to forget the forest for the trees, Johnson reminds Elon Musk fans that Tesla continues to rely heavily upon

Wall Street Journal US BusinessOct 27, 2020
Pandemic Dents Third-Quarter Sales for Pfizer
The Covid-19 pandemic weighed down sales for some drugs in the latest quarter as the company's candidate vaccine for the virus that has caused the public-health crisis continues in a large late-stage trial.

RELATED ARTICLES
Pfizer not yet ready to release COVID-19 vaccine data (Yahoo Business)

MarketWatch MarketPulseOct 27, 2020
Novavax's stock rises 3% as it announces plans to share Phase 2 vaccine data this week
Shares of Novavax Inc. gained 2.9% in trading on Tuesday after the company said it expects to launch a Phase 3 trial for its COVID-19 vaccine candidate in Mexico and the U.S. by the end of next month. It already started a late-stage trial for its vaccine in the U.K. in September. Novavax has published some data for its experimental COVID-19 vaccine from its Phase 1 clinical trial, in September in the New England Journal of Medicine. It said Tuesday it plans to present new reactogenicity data from the Phase 2 trial on Friday, during an advisory committee on immunization practices meeting convened by the Centers for Disease Control and Prevention. Novavax's stock has soared 2,180.1% so far this year, compared with the S&P 500 , which is up 5.2%.

Market Pulse Stories are Rapid-fire, short news bursts on stocks and markets as they move. Visit MarketWatch.com for more information on this news.



MarketWatch MarketPulseOct 27, 2020
Crocs shares rise after 'record' earnings report
Crocs Inc. shares rose 2.9% in Tuesday premarket trading after the shoe company reported better-than-expected third-quarter earnings and revenue. Net income totaled $61.9 million, or 91 cents per share, up from $35.7 million, or 51 cents per share, last year. Adjusted EPS of 94 cents were up from 57 cents last year and beat the FactSet consensus for 70 cents. Revenue of $361.7 million increased from $312.8 million last year and beat the FactSet consensus for $344.0 million. Digital sales rose 35.5%. Retail comparable sales jumped 16.2%. "We achieved record third-quarter revenue and EPS despite the challenges presented by the global COVID-19 pandemic," said Andrew Rees, chief executive officer of the company, in a statement. Cash and equivalents were $123.6 million as of Sept. 30. Excluding any potential impact from COVID-19-related shutdowns, Crocs is guiding for fourth-quarter revenue growth between 20% and 30%, and full-year revenue growth of 5% to 7%. FactSet forecasts fourth-quarter revenue of $286.0 million, suggesting 8.8% growth, and full-year revenue of $1.24 billion, implying a 1% rise. Crocs stock has rallied 24.7% for the year to date while the S&P 500 index is up 5.3% for the period.

Market Pulse Stories are Rapid-fire, short news bursts on stocks and markets as they move. Visit MarketWatch.com for more information on this news.



RELATED ARTICLES
3M's stock ticks up after profit beats expectations, sales rise just above forecasts (MarketWatch MarketPulse)
USA Today MoneyOct 26, 2020
Home Depot releases Black Friday sales ad with deals starting Nov. 6 amid coronavirus pandemic
Home Depot's Black Friday 2020 sale runs Nov. 6 through Dec. 2 amid the COVID-19 pandemic. The holiday deals will be available while supplies last.      

Google Business NewsOct 26, 2020
'Critical juncture': Little moves Idaho back to Stage 3 amid sustained coronavirus surge - East Idaho News
'Critical juncture': Little moves Idaho back to Stage 3 amid sustained coronavirus surge  East Idaho NewsIdaho governor orders return to some COVID-19 gathering restrictions as infections surge  oregonlive.comIdaho moves back to Stage 3 amid healthcare capacity constraints statewide  East Idaho NewsIdaho moves back to Stage 3, but with no mask mandate or enforcement, will it do any good?  Idaho Statesman

Yahoo BusinessOct 26, 2020
NIAID Study Finds Eli Lilly's Antibody Drug Unhelpful For Hospitalized COVID-19 Patients
Eli Lilly and Company (NYSE: LLY) said Monday that a trial of its antibody treatment for use in hospitalized COVID-19 patients has come to an end as the treatment is unlikely to help such patients. What Happened: The one of its kind study -- conducted by the National Institute of Allergy and Infectious Diseases, part of the National Institutes of Health -- was evaluating the efficacy of bamlanivimab, according to a statement issued by the company.Eli Lilly said that trial data has led to the recommendation that the treatment is unlikely to help hospitalized COVID-19 patients recover from an advanced stage of the disease.Other studies investigating bamlanivimab will continue, including an NIH-sponsored study evaluating the efficacy of the treatment in mild-to-moderate COVID-19 cases and the company's own Phase 2 trial in people recently diagnosed with COVID-19 in a non-hospitalized setting.Why It Matters: The Indianapolis, Indiana-based drug giant said it has submitted for an emergency use authorization for bamlanivimab based on its own Phase 2 trial results.This month, the drugmaker halted the Phase 3 trial of its antibody treatment due to a "potential safety concern." It was reported earlier that the Eli Lilly plant being readied to make the antibody treatment for COVID-19 was found to have serious quality control problems by the United States Food and Drug Administration.President Donald Trump was administered a similar antibody treatment from Regeneron Pharmaceutic
TRENDING TAGS
stockmarket COVID-19 surge Cases profit
Stockssurge Covid-19 European My Cases
COVID-19cases stocks surge How European
earningsCall Transcript Q3 Inc shares
Coronaviruscases latest pandemic Dow high
Salesprofit expectations Pandemic Fall 3M
buybillion AMD Xilinx Stock Stocks
profitMy beats sales outlook expectations
pandemiccoronavirus How Sales amid During
ElectionDay How Stock Market one

NEWS SOURCES
Top News (Business News)
Accounting Today
AdWeek News
Banking Business Review
Barron's This Week Magazine
Barron's Up and Down Wall Street Daily
Brad Ideas
Chicago Tribune Business News
CNBC Business
CNBC Economy
CNBC Finance
CNN/Money
CNN/Money Real Estate News
Dismal.com: Analysis
Dismal.com: Indicators
Enterprise Application News
Entrepreneur.com
Forbes Headlines
Forbes Social Media News
FT.com - China, Economy & Trade
FT.com - Financial Markets
FT.com - Hedge Funds
FT.com - Telecoms
FT.com - US
Google Business News
Google Market News
HBS Working Knowledge
Inc.com
INSEAD Knowledge
International Tax Review
Kiplinger
Knowledge@Wharton
L.S. Starrett News
MarketWatch
MarketWatch Breaking News
MarketWatch MarketPulse
McKinsey Quarterly
MSNBC.com: Business
Nielsen Trends
NonProfit Times
NPR Topics: Business
NYTimes Business
OpinionJournal.com
Private Equity Breaking News
Reuters Business
Reuters Company News
Reuters Money
SEC.gov Updates: News Digest
SHRM HR News
Tax Policy News
The Economist International News
The Motley Fool
USA Today Money
Wall Street Journal US Business
Wall Street Transcript
Washington Post Business
WSJ Asia
WSJ Europe
WSJ MoneyBeat
WSJ Opinion
WSJ US News
WSJ World Markets
Yahoo Business
  • CEOExpress
  • 1 Boston Place | Suite 2600
    Boston MA 02108
  • 617 482 1200
    617 299 8649 (fax)
  • Contact
  • As an Amazon Associate
    CEOExpress earns from
    qualifying purchases.

©1999-2020 CEOExpress Company LLC